Eli Lilly Stock Surges on Stellar Q3 Earnings Performance
Eli Lilly (LLY) shares rallied sharply Thursday after the pharmaceutical giant reported third-quarter earnings that demolished analyst expectations. Adjusted EPS of $7.02 soared nearly 500% year-over-year, eclipsing the $5.69 consensus estimate.
Revenue growth proved equally impressive, with $17.6 billion in sales representing a 54% annual jump and beating forecasts by over $1.5 billion. The blockbuster results underscore Lilly's continued dominance in key therapeutic markets.